Eiger BioPharmaceuticals, Inc. (EIGR)

0.3300 -0.0400 (-10.81%) At close: 04:00PM EDT

Eiger BioPharmaceuticals, Inc.

2155 Park Boulevard
Palo Alto, CA 94306
United States
650 272 6138
https://www.eigerbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 56

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. David Apelian M.B.A., M.D., MBA, Ph.D.	CEO & Director	204.39k	N/A	1965
Dr. Jeffrey S. Glenn M.D., Ph.D.	Scientific Founder & Independent Director	67k	N/A	1963
Mr. Eldon C. Mayer III, M.B.A.	Chief Commercial Officer	586.96k	N/A	1961
Mr. William G. Kaichoff CPA, CPA	CFO and Principal Financial & Accounting Officer	N/A	N/A	1966
Mr. Christopher A. Kurtz	Chief Technical Officer	N/A	N/A	1967
Mr. James Vollins J.D.	Gen. Counsel, Chief Compliance Officer & Corp. Sec.	N/A	N/A	1969
Dr. Ingrid C. Choong	Sr. VP of Clinical Devel.	N/A	N/A	N/A
Dr. Colin Hislop M.D., MBBS	Sr. VP of Clinical & Devel. Operations	N/A	N/A	1958

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Corporate Governance

Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 9. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.